Indication: T-Cell Lymphoma

Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma

Relapsed/refractory

Line of Therapy: Relapsed/Refractory T-cell Lymphoma

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Rhizen Pharmaceuticals

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.